{"public_id":"cl_8c8784c6d3f1d5c9c5fbe24695ae8f83","status":"active","superseded_by_public_id":null,"corpus_id":2237119,"text":"Novel agents such as lenalidomide and ibrutinib, used alone or in combination with rituximab-based chemotherapy, have demonstrated promising activity in patients with relapsed/refractory diffuse large B-cell lymphoma.","confidence":0.85,"paper":{"corpus_id":2237119,"title":"Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review","url":"https://sah.borca.ai/papers/2237119"},"contributors":[{"id":170,"public_id":"gsgmdx9r6e","public_label":"pupuri (gsgmdx9r6e)","roles":["extraction"],"url":"https://sah.borca.ai/u/gsgmdx9r6e"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0addbd75eec3181bcf23a56fc30ec09b","name":"relapsed/refractory diffuse large B-cell lymphoma","description":"Diffuse large B-cell lymphoma that has recurred after treatment or failed to respond to standard chemotherapy.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_0addbd75eec3181bcf23a56fc30ec09b"},{"public_id":"co_a414a373aba591ef63d9eed93c08587d","name":"ibrutinib","description":"A Bruton's tyrosine kinase inhibitor used as a novel agent in the treatment of relapsed/refractory DLBCL.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_a414a373aba591ef63d9eed93c08587d"},{"public_id":"co_b5b1f16587615f966f21f71cfb7a7e2f","name":"lenalidomide","description":"An immunomodulatory drug used as a novel agent in the treatment of relapsed/refractory DLBCL.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_b5b1f16587615f966f21f71cfb7a7e2f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_8c8784c6d3f1d5c9c5fbe24695ae8f83"}